Merck & CompanyvsNeumora Therapeutics

MRK and NMRA stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

NMRA

Neumora Therapeutics, Inc.

$0.33

Value $61M

-3.75%
NMRA's page

Merck & Company (MRK) has a market value of $331B and Neumora Therapeutics (NMRA) $61M. Over the last year, with dividends, MRK moved +44.8% and NMRA -86.9%. Dividend yield: MRK 2.54%, NMRA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$331B

    NMRA$61M

    MRK is 5,439 times NMRA

  • Revenue, 12 months

    MRK$67.4B

    NMRA–

  • Net income, 12 months

    MRK$2.5B

    NMRA-$190M

  • Operating margin

    MRK–

    NMRA–

  • ROIC

    MRK3.9%

    NMRA-87.2%

    91.1 points apart

  • P/E

    MRK134.8

    NMRA–

  • Dividend yield

    MRK2.5%

    NMRA0.0%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+42.7%

NMRA-97.2%

050100150202420252026
Returns by period
PeriodMRKWith dividendsNMRAWith dividends
1 year since November 19, 2025+44.8%Price +40.7%-86.9%Price -86.9%
3 years since November 20, 2023+42.7%+12.6% a yearPrice +30.2%-97.2%-69.6% a yearPrice -97.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyNMRANeumora Therapeutics

Valuation

MRKNMRA
Valuation
Price$133.72$0.33
Market value$331B$61M
Enterprise value (EV)$375B$88M
P/E134.8–
P/E, 5-year median14.8–
P/B7.43.3
EV/EBIT78.7–
Free cash flow yield4.5%–

Results and growth

MRKNMRA
Results and growth
Revenue, 12 months$67.4B–
Net income, 12 months$2.5B-$190M
Free cash flow, 12 months$14.7B-$167M
Earnings per share, 12 months$0.98-$1.06
Revenue growth, year on year1.3%–
Revenue growth a year, past+9.4%over 5 years–
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKNMRA
Margins and returns on capital
Gross margin71.8%–
Operating margin––
Net margin3.6%–
ROIC3.9%-87.2%
ROE5.2%-257.5%

Balance sheet

MRKNMRA
Balance sheet
Cash$9.7B$86M
Total debt$53.8B$114M
Net debt / EBITDA5.7–
Interest cover2.4×-44.1×

Dividends and buybacks

MRKNMRA
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.5%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or NMRA

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Neumora Therapeutics?

By market value, Merck & Company ($331B) is about 5,439.1 times Neumora Therapeutics ($61M), at today's prices.

How did MRK and NMRA stock do over the last 3 years?

Since November 20, 2023, MRK's price moved +30.2% and NMRA's -97.2%. With dividends: MRK +42.7% (+12.6% a year), NMRA -97.2% (-69.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or NMRA?

The dividend yield at today's price is 2.54% for Merck & Company and none for Neumora Therapeutics. Over the last twelve months they paid $3.40 and – per share.

Which is the better investment, Merck & Company or Neumora Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.